The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year. Drugs (Pharmaceuticals), Company Reports, GLP-1 RAs (Drug), International Trade and World Market, Novo Nordisk A/S, Jorgensen, Lars Fruergaard The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year. NYT > Business
Novo Nordisk Annual Sales Jump on Demand for Ozempic and Wegovy
